A Phase 3 interventional study of Boostrix™ and ADACEL® in Acellular Pertussis, Diphtheria and Tetanus, sponsored by GlaxoSmithKline. Completed at 42 sites in United States. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-07.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing boostrix in Diphtheria — 3 open to participants now, 3 under way, none of them phase 3. Boostrix · Diphtheria.
Among the 21 studies testing boostrix in Diphtheria, this one has the largest enrollment, is one of 4 that started in 2006, is one of 10 in phase 3, and was the 3rd registered.
267 studies on the registry are indexed under Diphtheria; 17 are open to participants now.
Browse Diphtheria studies →3 of the 21 studies testing boostrix in Diphtheria are open now, in 2 countries. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Canadian Immunization Research Network · Sites in Canada
Ages 18–49 · Women only
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2006.
This study's enrollment of 2,337 is above the median of 448 across 241 interventional studies indexed under Diphtheria.
Median enrollment 460 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
101 studies in Diphtheria by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 99 finished, 59 (60%) have results posted.
Among the 101 studies in Diphtheria by GlaxoSmithKline, this one is the 4th largest by enrollment of the 92 interventional ones that give a count, is one of 12 that started in 2006, is one of 55 in phase 3, and was the 28th registered.
GlaxoSmithKline’s Diphtheria studies by the year they started, since 1997.
1 of the studies testing boostrix in Diphtheria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07097012Canadian Immunization Research NetworkConcurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing boostrix in Diphtheria, from their registry updates:
Among GlaxoSmithKline’s 101 in Diphtheria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years. The ACIP has recently issued provisional recommendations for universal adult Tdap vaccination. The current study will provide pivotal data in support of extending the age range for Boostrix vaccine to include adults 19-64 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
Biological: Boostrix™
Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
Biological: ADACEL®
Number of Seroprotected Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
A seroprotected subject is defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to ( ≥) 0.1 international units per milliliter (IU/mL).
Time frame: At Month 1
Number of Seropositive Subjects With Anti-tetanus (Anti-T) Antibodies
A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value. Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
Time frame: At Month 1
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Month 1
Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below cut-off: smaller than (\<) 5 EU/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration greater than or equal to (≥) 20 EU/mL), one month after vaccination; for initially seropositive subjects with pre-vaccination concentration ≥ 5 EU/mL and \< 20 EU/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EU/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration, one month after vaccination.
Time frame: At Month 1
Number of Seropositive Subjects With Anti-diphteria (Anti-D) Antibodies
A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value. Cut-off values assessed were greater than or equal to (≥) 1.0 international units per milliliter (IU/mL).
Time frame: At Month 1
Number of Subjects With Booster Responses for Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T)
Booster responses for anti-D and anti-T antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below cut-off: smaller than (\<) 0.1 IU/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration greater than or equal to (≥ 0.4 IU/mL), one month after vaccination; and for initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination.
Time frame: At Month 1
Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Month 1
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
Time frame: During the 15-day period (Day 0-14) following vaccination
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as temperature measured orally, greater than or equal to (≥) 37.5 degrees Celsius (°C)\], gastrointestinal symptoms \[gastro sympt.\] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 15-day period (Day 0-14) following vaccination
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day period (Days 0-30) following vaccination
Number of Subjects With Serious Adverse Events (SAEs).
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the active phase of the study (Day 0 - Day 30)
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the extended safety follow-up (ESFU) phase (Day 31 - Month 6)
Number of Subjects Reporting Hospitalizations
Hospitalization signified that the subject had been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or out patient setting.
Time frame: During the extended safety follow-up (ESFU) period (from Day 31 to Month 6)
Number of Subjects Reporting Emergency Room Visits
Emergency room visits refer to AEs requiring immediate medical attention.
Time frame: During the extended safety follow-up (ESFU) period (from Day 31 to Month 6)
Number of Subjects Reporting the Onset of New Chronic Illnesses
New onset chronic illnesses include diabetes, asthma, allergies, autoimmune diseases.
Time frame: During the extended safety follow-up (ESFU) period (from Day 31 to Month 6)
| Milestone | Boostrix Group | Adacel Group |
|---|---|---|
| Started | 1522 | 762 |
| Completed | 1481 | 738 |
| Not completed | 41 | 24 |
| Withdrew: Serious adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 39 | 24 |
A seroprotected subject is defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to ( ≥) 0.1 international units per milliliter (IU/mL).
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Anti-D | 1418 | 717 |
| Anti-T | 1439 | 728 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value. Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Seropositive Subjects With Anti-tetanus (Anti-T) Antibodies | 1420 | 723 |
Concentrations are presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Boostrix Group | Adacel Group |
|---|---|---|
| Anti-PT | 63.6 (60.1 to 67.4) | 32.2 (29.6 to 35.1) |
| Anti-FHA | 624.4 (593.9 to 656.6) | 368.4 (344.3 to 394.2) |
| Anti-PRN | 401.0 (368.5 to 436.3) | 351.9 (315.7 to 392.2) |
Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below cut-off: smaller than (\<) 5 EU/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration greater than or equal to (≥) 20 EU/mL), one month after vaccination; for initially seropositive subjects with pre-vaccination concentration ≥ 5 EU/mL and \< 20 EU/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EU/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration, one month after vaccination.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Anti-PT | 1095 | 338 |
| Anti-FHA | 1388 | 671 |
| Anti-PRN | 1343 | 665 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value. Cut-off values assessed were greater than or equal to (≥) 1.0 international units per milliliter (IU/mL).
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Seropositive Subjects With Anti-diphteria (Anti-D) Antibodies | 1269 | 669 |
Booster responses for anti-D and anti-T antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below cut-off: smaller than (\<) 0.1 IU/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration greater than or equal to (≥ 0.4 IU/mL), one month after vaccination; and for initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Anti-D | 1116 | 566 |
| Anti-T | 704 | 441 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Boostrix Group | Adacel Group |
|---|---|---|
| Anti-D | 4.7 (4.4 to 5.1) | 5.0 (4.6 to 5.4) |
| Anti-T | 8.5 (8.1 to 8.9) | 13.3 (12.5 to 14.1) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Pain, Any | 903 | 513 |
| Pain, Grade 3 | 24 | 17 |
| Redness, Any | 313 | 201 |
| Redness, ≥ 50 mm | 23 | 17 |
| Swelling, Any | 260 | 190 |
| Swelling, ≥ 50 mm | 21 | 21 |
Assessed solicited general symptoms were fatigue, fever \[defined as temperature measured orally, greater than or equal to (≥) 37.5 degrees Celsius (°C)\], gastrointestinal symptoms \[gastro sympt.\] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Fatigue, Any | 416 | 214 |
| Fatigue, Grade 3 | 37 | 9 |
| Fatigue, Related | 251 | 151 |
| Fever (orally), ≥37.5 °C | 82 | 59 |
| Fever (orally), ≥39 °C | 1 | 3 |
| Fever, Related | 40 | 28 |
| Gastro sympt., Any | 235 | 130 |
| Gastro sympt., Grade 3 | 18 | 10 |
| Gastro sympt., Related | 125 | 67 |
| Headache, Any | 445 | 230 |
| Headache, Grade 3 | 32 | 11 |
| Headache, Related | 245 | 143 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | 271 | 169 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs). | 9 | 2 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 12 | 11 |
Hospitalization signified that the subject had been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or out patient setting.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Subjects Reporting Hospitalizations | 13 | 10 |
Emergency room visits refer to AEs requiring immediate medical attention.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Subjects Reporting Emergency Room Visits | 13 | 6 |
New onset chronic illnesses include diabetes, asthma, allergies, autoimmune diseases.
| Participants | Boostrix Group | Adacel Group |
|---|---|---|
| Number of Subjects Reporting the Onset of New Chronic Illnesses | 2 | 3 |
Collected over Solicited local and general symptoms: during the 15-day (Day 0-14) follow-up period after vaccination; Unsolicited AEs: during the 31-day (Day 0-30) follow-up period after vaccination; SAEs: during the entire study period, including the ESFU phase (Month 0 - Month 6).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix Group | 1/1,522 (0.1%) | 21/1,522 (1.4%) | 1,108/1,522 (72.8%) |
| Adacel Group | 1/762 (0.1%) | 13/762 (1.7%) | 595/762 (78.1%) |
| Event | Boostrix Group | Adacel Group |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 3/1522 | 0/762 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/1522 | 0/762 |
| MenometrorrhagiaReproductive system and breast disorders | 2/1522 | 0/762 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1522 | 1/762 |
| Thermal burnInjury, poisoning and procedural complications | 0/1522 | 1/762 |
| Acute myocardial infarctionCardiac disorders | 0/1522 | 1/762 |
| AnaemiaBlood and lymphatic system disorders | 0/1522 | 1/762 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/1522 | 1/762 |
| Cerebrovascular accidentNervous system disorders | 0/1522 | 1/762 |
| GastritisGastrointestinal disorders | 0/1522 | 1/762 |
| Event | Boostrix Group | Adacel Group |
|---|---|---|
| PainGeneral disorders | 905/1522 | 516/762 |
| HeadacheNervous system disorders | 448/1522 | 230/762 |
| FatigueGeneral disorders | 419/1522 | 214/762 |
| ErythemaSkin and subcutaneous tissue disorders | 313/1522 | 201/762 |
| SwellingGeneral disorders | 261/1522 | 190/762 |
| Gastrointestinal disorderGastrointestinal disorders | 235/1522 | 130/762 |
| PyrexiaGeneral disorders | 82/1522 | 60/762 |
| Age, Continuous(Years) | Boostrix Group | Adacel Group | Total |
|---|---|---|---|
| Mean | 39.9 ± 13.64 | 40.1 ± 13.51 | 39.97 ± 13.59 |
| Sex: Female, Male(Participants) | Boostrix Group | Adacel Group | Total |
|---|---|---|---|
| Female | 946 | 479 | 1425 |
| Male | 576 | 283 | 859 |
| Race/Ethnicity, Customized(Participants) | Boostrix Group | Adacel Group | Total |
|---|---|---|---|
| Geographic ancestry — African heritage/African American | 126 | 61 | 187 |
| Geographic ancestry — American Indian or Alaskan native | 6 | 5 | 11 |
| Geographic ancestry — Asian - Central/South Asian heritage | 1 | 0 | 1 |
| Geographic ancestry — Asian - East Asian heritage | 2 | 1 | 3 |
| Geographic ancestry — Asian - Japanese heritage | 3 | 0 | 3 |
| Geographic ancestry — Asian - South East Asian heritage | 6 | 3 | 9 |
| Geographic ancestry — Native Hawaiian or other Pacific islander | 6 | 3 | 9 |
| Geographic ancestry — White - Arabic/North African heritage | 19 | 13 | 32 |
| Geographic ancestry — White - Caucasian/European heritage | 1281 | 635 | 1916 |
| Geographic ancestry — Not specified | 72 | 41 | 113 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Jul 2006 to primary completion in Mar 2007, 7 months.
Results were first posted in Aug 2018, 11 years 5 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 7 months is below that.
Counting every sponsor, half of 47 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Boostrix · Adacel